Core Insights - AstraZeneca has announced a strategic partnership with CSPC Pharmaceutical Group, involving an upfront payment of $1.2 billion and a potential total deal value exceeding $18.5 billion [2][3] - The collaboration focuses on developing innovative long-acting peptide drugs utilizing CSPC's proprietary sustained-release drug delivery technology and AI-driven peptide drug discovery platform [2][3] - CSPC's technology allows for monthly or longer dosing intervals, enhancing patient compliance for long-term medication [2][3] Partnership Details - The agreement includes the overseas rights for a weight management product combination, featuring a clinical-ready project SYH2082 (a long-acting GLP1R/GIPR agonist) and three preclinical projects targeting obesity and weight-related issues [3] - CSPC stands to gain $12 billion in upfront payments, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion for sales, along with a double-digit percentage royalty on net sales [3] Industry Context - GLP-1 has emerged as a revolutionary target in the fields of diabetes and weight loss, with the global competition in GLP-1 research entering its "second half" [3] - Pharmaceutical companies are focusing on next-generation innovative weight loss therapies, including oral small molecules and ultra-long-acting formulations to improve patient experience and efficacy [3] - This is not the first collaboration between AstraZeneca and CSPC, as they previously established a partnership in June 2025 with a potential value exceeding $5 billion, focusing on AI-driven oral small molecule drug development for chronic and immune diseases [3] Investment Plans - AstraZeneca plans to invest over 100 billion RMB (approximately $15 billion) in China by 2030 to expand its presence in drug manufacturing and R&D [3]

Core Insights - AstraZeneca has entered into a strategic research and licensing agreement with CSPC Pharmaceutical Group, involving an upfront payment of $1.2 billion and a potential total deal value exceeding $18.5 billion [1][3]. Group 1: Partnership Details - The collaboration allows AstraZeneca to utilize CSPC's proprietary sustained-release drug delivery technology and AI drug discovery platform for developing innovative long-acting peptide drugs [1]. - CSPC's long-acting technology enables sustained release of peptide drugs, allowing for administration intervals of once a month or longer, enhancing patient compliance for long-term treatment [1][3]. - The partnership includes the overseas rights for a weight management product portfolio, including a clinical-ready project SYH2082 (long-acting GLP-1R/GIPR agonist) and three preclinical projects targeting obesity and weight-related issues [3]. Group 2: Financial Aspects - CSPC will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and up to $13.8 billion for sales, along with a double-digit percentage royalty based on annual net sales of the licensed products [3]. - AstraZeneca plans to invest over 100 billion RMB (approximately $15 billion) in China by 2030 to expand its pharmaceutical production and R&D footprint [4]. Group 3: Industry Context - GLP-1 has emerged as a revolutionary target in the diabetes and weight loss sectors, with the global GLP-1 development race entering its "second half," focusing on next-generation innovative weight loss therapies [3]. - The collaboration is not the first between CSPC and AstraZeneca, as they previously established a strategic partnership in June 2025, with a potential value exceeding $5 billion, focusing on AI-driven oral small molecule drug development for chronic and immune diseases [3].

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has fallen over 10%, currently down 9.07% at HKD 9.72, with a trading volume of HKD 25.63 billion [1] Group 1: Strategic Partnership - CSPC Pharmaceutical Group announced a strategic cooperation and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs [1] - The collaboration includes a clinical-ready long-acting GLP-1/GIP dual-target agonist project SYH2082 and three preclinical projects, with plans to explore four additional new projects [1] Group 2: Financial Implications - The licensing agreement sets a new record for overseas business development transactions in the GLP-1 sector [1] - CSPC will receive an upfront payment of USD 1.2 billion, with potential milestone payments for research reaching up to USD 3.5 billion and sales milestone payments up to USD 13.8 billion [1] - Additionally, CSPC is entitled to a sales commission based on the annual net sales of related products, with the total potential transaction amounting to USD 18.5 billion [1]

Core Viewpoint - The stock of Stone Pharmaceutical Group (01093) has fallen over 10%, currently trading at 9.72 HKD with a transaction volume of 2.563 billion HKD following the announcement of a strategic collaboration and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs [1] Group 1: Strategic Collaboration - Stone Pharmaceutical Group has signed a strategic collaboration and licensing agreement with AstraZeneca covering a clinical-ready long-acting GLP-1/GIP dual-target agonist project SYH2082 and three preclinical projects [1] - The agreement also includes plans for collaboration on an additional four new projects [1] Group 2: Financial Terms - The collaboration sets a new record for overseas business development transactions in the GLP-1 sector, with Stone Pharmaceutical Group receiving a prepayment of 1.2 billion USD [1] - The company is entitled to receive up to 3.5 billion USD in potential research milestone payments and up to 13.8 billion USD in potential sales milestone payments [1] - Additionally, Stone Pharmaceutical Group will earn a sales commission based on the annual net sales of related products, with potential total transaction value reaching up to 18.5 billion USD [1]

Core Viewpoint - CSPC Pharmaceutical Group has entered into an agreement with UK drugmaker AstraZeneca to develop innovative long-acting peptide medicines targeting obesity and weight-related conditions [1] Company Summary - CSPC Pharmaceutical Group is collaborating with AstraZeneca, indicating a strategic move towards addressing the growing market for obesity treatments [1] - The partnership focuses on the development of innovative long-acting peptide medicines, which may enhance treatment options for patients suffering from obesity and related health issues [1] Industry Summary - The agreement highlights the increasing emphasis on innovative therapies in the pharmaceutical industry, particularly in the area of obesity management [1] - The collaboration reflects a broader trend in the industry towards partnerships aimed at leveraging expertise and resources to tackle significant health challenges [1]

石药集团(01093)发布公告，集团已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议，以 利用集团专有的缓释给药技术平台及多肽药物AI发现平台("该等平台")，开发创新长效多肽药物。 集团的长效技术可实现多肽药物的缓释，使给药间隔达到每月一次或更长。基于此平台开发的产品为即 用型，使用简便，支持患者自行给药，能有效提升长期用药人群的治疗依从性。同时，集团的多肽药物 AI发现平台可以针对药物靶点快速设计及筛选候选分子，并可在药效、选择性与信号偏向性等维度进 行系统优化。 根据该协议的条款，集团将与阿斯利康在创新多肽分子的发现和长效递送产品的开发方面开展全面战略 合作。除持续推进现有临床前长效多肽管线之外，集团亦将为阿斯利康发现和开发其他创新长效多肽产 品。 除中国内地、中国香港、中国澳门及中国台湾外，阿斯利康将获得集团每月一次注射用体重管理产品组 合的全球独家权利，包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临 床)，以及三个处于临床前阶段、具备不同作用机制的研发项目，旨在为肥胖及体重问题相关人群提供 更持久的治疗获益，双方还将依托该等平台就另外四个新增项目开展 ...

根据该协议的条款，集团将与阿斯利康在创新多肽分子的发现和长效递送产品的开发方面开展全面战略 合作。除持续推进现有临床前长效多肽管线之外，集团亦将为阿斯利康发现和开发其他创新长效多肽产 品。 除中国内地、中国香港、中国澳门及中国台湾外，阿斯利康将获得集团每月一次注射用体重管理产品组 合的全球独家权利，包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临 床)，以及三个处于临床前阶段、具备不同作用机制的研发项目，旨在为肥胖及体重问题相关人群提供 更持久的治疗获益，双方还将依托该等平台就另外四个新增项目开展合作。 按照该协议的条款及条件，集团将授予阿斯利康对相关授权产品在全球范围(不含中国内地、中国香 港、中国澳门及中国台湾)开发、生产和商业化的独家授权，同时将保留该等产品在中国内地、中国香 港、中国澳门及中国台湾的权益。就阿斯利康对八个项目及该等平台的使用，集团将获得12亿美元的预 付款，并有权获得最高35亿美元的潜在研发里程碑付款和最高138亿美元的潜在销售里程碑付款，以及 基于相关授权产品年净销售额的最高达双位数比例的销售提成。 石药集团(01093)发布公告，集团已与全球 ...

除中国内地、中国香港、中国澳门及中国台湾外，阿斯利康将获得集团每月一次注射用体重管理产品组 合的全球独家权利，包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临 床)，以及三个处于临床前阶段、具备不同作用机制的研发项目，旨在为肥胖及体重问题相关人群提供 更持久的治疗获益，双方还将依托该等平台就另外四个新增项目开展合作。 格隆汇1月30日丨石药集团(01093.HK)发布公告，集团已与全球生物制药领导者阿斯利康签订战略研发 合作与授权协议，以利用集团专有的缓释给药技术平台及多肽药物AI发现平台("该等平台")，开发创新 长效多肽药物。集团的长效技术可实现多肽药物的缓释，使给药间隔达到每月一次或更长。基于此平台 开发的产品为即用型，使用简便，支持患者自行给药，能有效提升长期用药人群的治疗依从性。同时， 集团的多肽药物AI发现平台可以针对药物靶点快速设计及筛选候选分子，并可在药效、选择性与信号 偏向性等维度进行系统优化。 根据该协议的条款，集团将与阿斯利康在创新多肽分子的发现和长效递送产品的开发方面开展全面战略 合作。除持续推进现有临床前长效多肽管线之外，集团亦将为阿斯利康发现 ...

（股份代號：1093） （於香港註冊成立之有限公司） 自願公告 與阿斯利康就創新長效多肽藥物開發簽訂戰略合作與授權協議 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團已與全球生物製藥領導者阿斯利康簽訂戰略研發合作與授權協議（「該協議」）， 以利用本集團專有的緩釋給藥技術平台及多肽藥物AI發現平台（「該等平台」），開發創新長 效多肽藥物。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 – 2 – – 1 – 除中國內地、香港特別行政區、澳門特別行政區及台灣地區外，阿斯利康將獲得本集團每 月一次注射用體重管理產品組合的全球獨家權利，包括一個臨床準備就緒的項目SYH2082 （ 長效GLP1R / GIPR激動劑，正推進至I期臨床 ），以及三 ...

智通财经APP讯，石药集团(01093)发布公告，集团开发的SYS6055注射液已获得中华人民共和国国家药 品监督管理局(NMPA)批准，可在中国开展临床试验。 本次获批的临床适应症为复发╱难治侵袭性B细胞淋巴瘤。此外，该产品亦具备用于治疗其他CD19阳 性的B细胞恶性肿瘤和自身免疫病的潜力，具有较高的临床开发价值。 该产品为国内首款获批临床的体内CAR-T产品，通过慢病毒载体在体内直接生成靶向CD19 的CAR-T细 胞，可特异性识别和清除靶细胞，从而达到治疗目的。与传统CAR-T产品相比，该产品在成本、可及性 和即时性等方面具备潜在优势。临床前研究显示，该产品可在体内特异性生成CAR-T细胞，具有显着的 抑瘤效果与良好的安全性，并具有成本和时间优势，有望为B淋巴细胞肿瘤患者提供更好的治疗选择。 ...